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1  | INTRODUC TION
Rapid developments in genomic technologies now mean that it is 
possible to screen newborn babies for larger numbers of conditions 
simultaneously than ever before. The development of tandem mass 
spectrometry, and the declining cost and increasing efficacy of whole 
genome/exome sequencing using technologies such as CRISPR‐Cas9 
now mean that high output mass screens are on the horizon, prompt‐
ing renewed interest in the potential population health and societal 
benefits of population‐based genomic screens.1‐4 By conducting untar‐
geted genome/exome sequencing, whole panels of genetic conditions 
can now be screened for from a single blood sample, as well as child's 
propensity to future diseases, and even their potential reactions to cer‐
tain medicines and drugs. As such, direct‐to‐consumer private genetics 
companies are already capitalizing on the value of this information to 
new parents by offering expansive newborn screens for a nominal fee.
Haemophilia is a potential candidate condition for newborn screen‐
ing being expanded to the general population, who have no known 
 
Received: 7 November 2018  |  Revised: 26 January 2019  |  Accepted: 27 January 2019
DOI: 10.1111/hae.13706
O R I G I N A L  A R T I C L E
Clinical haemophilia
Newborn screening for haemophilia: The views of families and 
adults living with haemophilia in the UK
Felicity K. Boardman1  |   Rachel Hale1 |   Philip J. Young2
1Division of Health Sciences, Warwick 
Medical School, University of Warwick, 
Coventry, UK
2School of Life Sciences, University of 
Warwick, Coventry, UK
Correspondence
Felicity K. Boardman, Division of Health 
Sciences, Warwick Medical School, 
University of Warwick, Coventry, UK.
Email: felicity.boardman@warwick.ac.uk
Funding information
Wellcome Trust, Grant/Award Number: 
203384/Z/16/Z
Introduction: As genomic sequencing become more efficient and cost‐effective, the 
number of conditions identified through newborn screening globally is set to dra‐
matically increase. Haemophilia is a candidate condition; however, very little is known 
about the attitudes of the haemophilia community towards screening.
Aim: This study aimed to outline the perspectives of adults with haemophilia and 
their families towards newborn screening.
Methods: A paper and online survey on screening were distributed to every family 
known to the Haemophilia Society UK. Data collection occurred between January 
and June 2018. In total, 327 participants completed the survey: 76% were a relative 
of a person with haemophilia and 24% had haemophilia themselves; 83% were living 
with haemophilia A and 17% with haemophilia B.
Results: The vast majority supported newborn screening (77%) and preferred it to 
other forms of screening (preconception or prenatal). Participants supported new‐
born screening primarily because they viewed it as a means to facilitate early support 
and treatment, facilitate informed decisions about future pregnancies and prevent 
the “diagnostic odyssey.” The 23% who did not support the screen did not associate 
these particular benefits with newborn screening.
Conclusion: Haemophilia emerged from this analysis as a condition that the vast ma‐
jority of participants considered a “liveable” disability and one best suited to newborn 
screening programmes that could improve support to affected families rather than 
reduce the birth rate of affected children.
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family history of the condition. Affecting one in every 5000 male new‐
borns worldwide (haemophilia A) and 1 in 30 000 male newborns (hae‐
mophilia B), it is the most severe form of X‐linked inherited bleeding 
disorder. Moreover, as the most serious type of bleed for those with 
haemophilia (intracranial haemorrhage) is most likely to occur during 
the neonatal period, and with about half of these babies having no fam‐
ily history of a bleeding disorder, newborn screening for the condition 
can also be justified on the grounds of protecting the health of both the 
infant, but also the mother who may have some bleeding symptoms.5
Given the perceived disease burden associated with haemo‐
philia, however, research into population screening has previously 
generally focused attention on the prenatal or preconception pe‐
riod rather than the newborn period.6 However, with the advent 
of new treatments, particularly early prophylactic treatment that 
uses recombinant clotting factors, means that the disease burden 
of haemophilia is slowly evolving, altering the landscape of genetic 
screening.7 Indeed, the frequently observed contrast between the 
experiences of younger generations growing up with haemophilia 
and those of older generation haemophiliacs—many of whom were 
exposed to blood‐borne viruses such as Hepatitis B/C and HIV 
through contaminated blood in the 1970s and 1980s—suggests that 
an exploration of current attitudes towards screening for haemo‐
philia amongst the affected community is now particularly timely.8,9
Whilst the acceptability of newborn screens to (expectant) par‐
ents is a topic that has been widely explored in relation to a range of 
different conditions,10‐12 and is a key component in the assessment 
of screening programmes conducted by the UK National Screening 
Committee, the views of affected families and adults have been 
less extensively researched.10,12‐14 This omission is striking given 
that the “hands on” direct experience possessed by these families 
uniquely positions them to consider what an early screen would 
have meant for them.10 Furthermore, screening has impacts for af‐
fected families that go beyond those anticipated for the general 
population. These include the social implications (for example, stig‐
matization) that come along with a shift in the “public profile” of the 
condition,15 but also a potential decrease in the condition's preva‐
lence (as has already been observed in relation to Cystic Fibrosis 
since the introduction of newborn screening16),with associated im‐
plications for how the condition is prioritized in the context of the 
allocation of public funding for research into treatments.17
To address this identified gap in the literature, this study pres‐
ents data on attitudes towards newborn genetic screening amongst 
people living with haemophilia A and/or B, either through having 
the condition themselves, or having affected relatives. By drawing 
on a national UK survey of families living with haemophilia, this 
paper contributes to an emerging area of the literature that consid‐
ers the social and ethical of dimensions of screening practices from 
the vantage point of those already living with the disease.10,12‐14,16
2  | MATERIAL S AND METHODS
This study reports on quantitative data that formed part of a 
larger exploratory sequential mixed methods study on attitudes to 
different types of screening programme across families living with 
various genetic conditions.12,18,19
Through the use of an advertisement in the newsletter of the 
UK Haemophilia Society, 22 adults with haemophilia and family 
members of people with haemophilia were recruited to partici‐
pate in qualitative interviews that took place between April 2017 
and March 2018. Seventeen interviews were conducted by tele‐
phone, and four interviews were conducted in person. The inter‐
view participants varied in terms of their ages, backgrounds and 
experiences with haemophilia as well co‐morbidities (associated 
with contaminated blood). The final sample included eight males 
with haemophilia and fifteen female relatives. The interviews 
explored participants’ experiences with haemophilia, their views 
on the condition's impact and their experiences of, and attitudes 
towards, reproductive genetic technologies. A thematic analysis 
was carried out on the qualitative interviews, and a survey, the 
Haemophilia Screening Survey (UK), directly developed from 
this analysis in order to measure both the significance and gen‐
eralizability of the expressed ideas. The core themes were used 
to delineate the key domains of the survey, and, where possible, 
verbatim data extracts from interview participants were used 
to create attitude statement questions, accompanied by a likert 
scale. Demographic questions were replicated, or appear as mod‐
ified versions of those included in the 2011 UK Census survey. 
Ethical approval for the survey was granted by the Biomedical and 
Scientific Research Ethics Committee in November 2017.
Survey data collection took place between January and June 
2018. Participants were invited to complete it if they either had 
haemophilia A or B themselves or had the condition in their fam‐
ily. No restrictions were placed on the nature of the familial rela‐
tionship, so step, adopted and fostered family members were all 
included.
A paper version of the survey was initially mailed to the 3000 
households affected by haemophilia that were known to the 
Haemophilia Society UK, and an online version was made available 
and distributed through the Haemophilia Society's online networks. 
The link was also disseminated through the social networks associ‐
ated with the research project. Participants were encouraged to dis‐
tribute the survey to relevant family/friends. Postal survey returns 
were all processed using data scanning technology to reduce human 
error.
The attitudes of family members and adults with haemophilia 
(AwH) towards newborn genetic screening (NGS) were compared 
to determine whether there were any statistical differences using a 
chi‐squared analysis (Graphpad Prism software, v6).
3  | RESULTS
3.1 | Demographic data
In total, 327 people returned either an online (33/327) or postal sur‐
vey (294/327). Of these, 148/327 (45%)were family members and 
179/327 (55%) were AwH (Table 1); 173/327 (53%) participants were 
male (Table 1), including 21/148 (14%) family members and 152/179 
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(85%) AwH (Table 1). Overall, most participants were associated with 
haemophilia A (273/327, 83%), broken down into 127/148 (86%) 
family members and 146/179 (82%) AwH (Table 1).
3.2 | Newborn genetic screening (NGS)
Overall, 253/327 (77%) supported NGS. However, there was a ten‐
dency towards less support for NGS in AwH: 132/179 (74%) than 
family members (Families: 121/148 (82%); Table 2).
The key reasons driving support for NGS was a belief that it 
would lead to better support, would allow parents to make informed 
decisions about future pregnancies and would spare parents the 
difficulties associated with a later diagnosis (Table 2). Participants 
also believed than an early screen could extend life expectancy and 
would allow earlier enrolment on clinical trials (Table 2). Most par‐
ticipants agreed that NGS is important even if severity could not be 
determined accurately at birth in all cases (Table 2).
Less than half of the participants agreed that NGS is unethical 
because of the lack of curative treatment available (a common eth‐
ical argument used against the introduction of NGS) or the notion 
that by using NGS, and not other forms of screening (such as precon‐
ception or prenatal screening), that NGS denies parents the choice 
as to whether or not they want to bring children affected by haemo‐
philia into the world in the first place (Table 2). Similarly, less than 
half the sample agreed that newborn screening would stop families 
and children enjoying life whilst they were still symptom‐free and 
most disagreed with the idea that receipt of a serious diagnosis early 
in life would interfere with parent‐child bonding (Table 2).
Interestingly, no significant differences in support for NGS were 
observed between those participants who came from families with 
multiple (>2) affected members as compared to those families who 
had only one or two members with haemophilia (Table 3).
74/327 (23%) responders did not support NGS: 27/148 (18%) 
families and 47/179 (26%) AwH (Table 4). Sub‐analysis of these re‐
sponders highlights that in general they did not believe introducing 
NGS would extend life expectancy or increase enrolment on clinical 
trial. However, although this 23% of responders did not personally 
support NGS introduction, they did not believe NGS would reduce 
presymptomatic quality of life, interfere with the parent‐child bond‐
ing process, make the diagnosis easier to accept for the parents or 
believe that it is unethical to screen newborn babies for diseases that 
cannot be treated (Table 4).
4  | DISCUSSION
This study, to the best of our knowledge, is the first to explore atti‐
tudes towards newborn screening amongst families and AwH. It has 
revealed that most adults with, and families affected by, haemophilia 
are in favour of newborn screening for the condition. With the in‐
creasing use of whole genome sequencing techniques for screening 
purposes, the introduction of newborn screening for conditions such 
as haemophilia could mark the advent of a new era in the manage‐
ment of the condition, including the possibility of using new non‐fac‐
tor drugs on these patients with very early diagnoses. Indeed, even 
the 23% of participants who did not support newborn screening in 
this study did so not because they necessarily held negative beliefs 
about newborn screening (for example, that it may affect parent/
child bonding or extend the illness into the presymptomatic period) 
but rather because they were unconvinced that newborn screening 
would confer the particular advantages cited by screening support‐
ers. As such, this study did not uncover overtly negative views about 
this type of screening programme.
There were some differences, however, in responses between 
AwH, who are mostly male, and responding family members, who 
are mostly female, with female relatives more likely to support NGS 
than affected males; although these differences are not significant, 
TA B L E  1   Characteristics and demographics of survey 
responders
Characteristic
All 
Responders 
(n = 327)
Families 
(n = 148) AwH (n = 179)
Gender ‐ no. (%)
Male 173 (53%) 21 (14%) 152 (85%)
Female 154 (47%) 127 (86%) 27 (15%)
Age
18‐25 y 11 (3%) 1 (1%) 10 (6%)
26‐34 y 38 (12%) 22 (15%) 16 (9%)
35‐45 y 68 (21%) 45 (30%) 23 (13%)
46‐55 y 60 (18%) 21 (14%) 39 (22%)
56‐65 y 65 (20%) 30 (20%) 35 (19%)
>65 y 85 (26%) 29 (20%) 56 (31%)
Qualifications
Degree or 
higher
142 (43%) 70 (47%) 72 (40%)
Other/none 185 (57%) 78 (53%) 107 (60%)
Religious
Yes 183 (56%) 88 (60%) 95 (53%)
No 130 (40%) 55 (37%) 75 (42%)
Prefer not to 
say
14 (4%) 5 (3%) 9 (5%)
Parents
Yes 253 (77%) 135 (91%) 118 (66%)
No 73 (22%) 12 (8%) 61 (24%)
Prefer not to 
say
1 (1%) 1 (1%) 0
Type of Haemophilia
Haemophilia A 273 (83%) 127 (86%) 146 (82%)
Haemophilia B 54 (17%) 21 (14%) 33 (18%)
Demographics are shown for all responders (n = 327), responders associ‐
ated with haemophilia families (families; n = 148) and adults with haemo‐
philia (AwH; n = 179)
Variables with significant differences (P < 0.05) are highlighted.
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they are approaching significance (P = 0.08). It is possible that this 
difference highlights the scepticism on the part of AwH regarding 
any tangible differences that NGS would have made to their own 
lives, particularly as none of them had benefitted from the early 
interventions offered to boys with haemophilia today, such as the 
commencement of prophylaxis. Indeed, many had, in fact, developed 
TA B L E  2   Response summaries for questions assessing views on newborn genetic screening (NGS)
Question All Responders (n = 327) Families (n = 148) AwH (n = 179)
F v AwH (chi‐2)
P Value
Identifying haemophilia/bleeding disorders at birth would lead to better support and health care for the child and their family
Agree 291 (89%) 134 (91%) 157 (88%) 0.66
Other 36 (11%) 14 (9%) 22 (12%)
Identifying haemophilia/bleeding disorders at birth would extend the life expectancy of a child with a bleeding disorder
Agree 212 (65%) 91 (61%) 121 (68%) 0.24
Other 115 (35%) 57 (39%) 58 (32%)
Identifying haemophilia/bleeding disorders at birth (and not in pregnancy) takes away the parents right to make a decision about whether or not 
they want to have a child with a bleeding disorder
Agree 107 (33%) 44 (30%) 63 (35%) 0.29
Other 220 (67%) 104 (70%) 116 (65%)
Identifying haemophilia/bleeding disorders before a child develops any symptoms prevents the child and their family from enjoying life whilst 
they are still symptom‐free
Agree 96 (29%) 38 (26%) 58 (32%) 0.18
Other 231 (71%) 110 (74%) 121 (68%)
Identifying haemophilia/bleeding disorders at birth would help research into a cure by enabling more children to be enrolled into clinical trials 
early on
Agree 198 (61%) 90 (61%) 108 (60%) 0.93
Other 129 (39%) 58 (39%) 71 (40%)
Identifying haemophilia/bleeding disorders at birth would interfere with the early bonding process between parent and child
Agree 18 (6%) 10 (7%) 8 (4%) 0.36
Other 309 (94%) 138 (93%) 171 (96%)
Identifying haemophilia/bleeding disorders at birth would make the diagnosis easier for parents to accept
Agree 177 (54%) 74 (50%) 103 (58%) 0.17
Other 150 (46%) 74 (50%) 76 (42%)
Identifying haemophilia/bleeding disorders at birth would spare parents the difficulties associated with finding a diagnosis for the child later on
Agree 254 (78%) 118 (80%) 136 (76%) 0.41
Other 73 (22%) 30 (20%) 43 (24%)
Even if parents could not know for sure the severety of the haemophilia/bleeding disorder affecting their newborn baby, its still better that they 
know about the bleeding disorder straight away
Agree 284 (87%) 130 (88%) 154 (86%) 0.63
Other 43 (13%) 18 (12%) 25 (14%)
Identifying haemophilia/bleeding disorders at birth is important as it would enable parents to make informed decisions about future pregnancies
Agree 266 (81%) 123 (83%) 143 (80%) 0.45
Other 61 (19%) 25 (17%) 36 (20%)
It is unethical not to screen newborn babies for conditions that can be treated
Agree 144 (44%) 67 (45%) 77 (43%) 0.68
Other 183 (56%) 81 (55%) 102 (57%)
I would support a newborn genetic screening programme for haemophilia/bleeding disorders
Agree 253 (77%) 121 (82%) 132 (74%) 0.08
Other 74 (23%) 27 (18%) 47 (26%)
Response breakdowns are shown for families and AwH. Responses for each question were stratified as “agree” v “other” (other=disagree and neither 
disagree nor agree).
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other serious co‐morbidities during the course of their treatment, 
such as Hepatitis B/C or HIV, which may have also influenced their 
perceptions of medical interventions.
The female relatives of AwH, however, viewed NGS from an 
entirely different vantage point. While not having experienced hae‐
mophilia directly themselves, the female relatives were nevertheless 
more heavily implicated, both socially as mothers, but also physically, 
as carriers, in their reproductive outcomes than their male counter‐
parts, which may have affected their perceptions of their responsi‐
bilities with regards to their family's health.20 It is also possible that 
such family members may also have a more clear memory of a diag‐
nostic odyssey, associated with later diagnosis, and may thus more 
clearly be able to envisage the benefits of early identification for 
boys with haemophilia. We found similar differences between family 
members and AwH in our work on attitudes to preconception and 
prenatal screening for haemophilia.19
In spite of these differences between AwH and family members, 
however, support for NGS was nevertheless high. These findings, 
when interpreted alongside the qualitative data, suggest that the 
participants do not view haemophilia (even in its most severe form) to 
be a condition that justifies selective reproduction through precon‐
ception or prenatal screening programmes. Rather, our data suggest 
that participants perceived haemophilia as a “liveable” condition, and 
emphasized the importance of early identification (even if severity 
is initially unknown) in order to minimize the time to diagnosis and 
treatment, as well as to reduce the risks of intracranial bleeds and 
joint damage that can be associated with untreated haemophilia.6
These findings are in line with our previous work assessing sup‐
port for prenatal screening for haemophilia, which found that af‐
fected adults and their family members in support of this form of 
screening do so not because they believe that selective pregnancy 
termination is an essential option, but rather because they believe 
that prenatal screening can provide vital information to prepare 
for the birth of a haemophiliac child, and also to protect the carrier 
mother.5
However, in spite of this scepticism around the reproductive 
value of screening for haemophilia, there was nevertheless support 
for the idea that NGS could be used by the parents of already af‐
fected children, to inform decisions about their future pregnancies. 
This finding is noteworthy as it suggests that the reproductive de‐
cisions and attitudes of already affected families are viewed dif‐
ferently by the haemophilia community than those made by the 
general population, highlighting the positive way that “experiential 
knowledge” and insight are valued in the appraisal of future af‐
fected lives.21,22 Indeed, the families and adults who participated in 
this survey had direct—and often extensive—knowledge of life with 
haemophilia, with 136/327 participants (42%) (Table 3) of the sam‐
ple having more than two people in their family living with haemo‐
philia—a much higher rate of inter‐family recurrence than has been 
noted by studies of screening attitudes within families affected by 
other genetic conditions.21
Overall, therefore, this study highlights the rich and complex 
insights that families living with genetic disorders bring to debates 
around expansive screening programmes. It is critical that any 
screening programme for haemophilia has an infrastructure that 
is able to capture and accurately reflect the reality of life with the 
condition, as this is likely to be different to the perceptions of hae‐
mophilia within the general public.22 The inclusion of families and 
AwH into screening policy debates is a key mechanism by which this 
change can occur.
4.1 | Further research/Policy implications
This study underscores the importance of consulting affected 
families when evaluating and implementing genetic screening 
programmes. Indeed, these groups have much to offer an under‐
standing of the realities of genetic impairment, a form of knowl‐
edge that will only become more significant as genomic medicine 
expands and decisions will need to be made regarding which 
conditions should be included on genetic screening panels, and 
which should not. Indeed, further research could usefully explore 
the knowledge and views of the general public towards screening 
for haemophilia in order to identify differences and similarities 
in their perceptions of the condition, as well as to inform and fa‐
cilitate the development of mechanisms of decision support as 
reproductive decisions become invariably more complex for the 
whole of society.
4.2 | Strengths and weaknesses
Recruiting through a support group, and not clinics, may have im‐
posed sample bias to the analysis as support groups are more likely to 
attract people experiencing difficulty, and those who value particu‐
lar forms of support. Indeed, it is noteworthy that a high proportion 
of women with haemophilia (15%) participated in the study, which 
might be explained by the methods of recruitment, given that sup‐
port groups are disproportionately accessed by women. Moreover, 
due to confidentiality and data protection requirements, no identi‐
fiable information was asked of participants. Whilst this may have 
aided recruitment, there was no means by which to prevent a partici‐
pant from completing multiple surveys. In spite of these weaknesses, 
however, the final sample was nevertheless diverse.
TA B L E  3   Support for NGS among families associated with 
increased numbers of people with haemophilia
 Other Agree Total
Associated with <2 
affected individuals
42 (22%) 149 (78%) 191
Associated with 
2 + affected individuals
32 (24%) 104 (76%) 136
P = 0.74 327
The support was compared for responders associated with <2 affected 
individuals compared with those associated with 2 + affected individu‐
als. Numbers and overall percentages are shown.
Differences were assessed using chi‐2 analysis (P‐value).
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Question
Responders who do not support NGS
All Responders 
(n = 74) Families (n = 27) AwH (n = 47)
F v AwH
P Value
Identifying haemophilia/bleeding disorders at birth would lead to better support and health 
care for the child and their family
Agree 44 (59%) 15 (56%) 29 (62%) 0.63
Other 30 (41%) 12 (44%) 18 (38%)
Identifying haemophilia/bleeding disorders at birth would extend the life expectancy of a child 
with a bleeding disorder
Agree 34 (46%) 13 (48%) 21 (45%) 0.81
Other 40 (54%) 14 (52%) 26 (55%)
Identifying haemophilia/bleeding disorders at birth (and not in pregnancy) takes away the 
parents right to make a decision about whether or not they want to have a child with a 
bleeding disorder
Agree 17 (23%) 5 (19%) 12 (26%) 0.57
Other 57 (77%) 22 (81%) 35 (74%)
Identifying haemophilia/bleeding disorders before a child develops any symptoms prevents the 
child and their family from enjoying life whilst they are still symptom‐free
Agree 15 (20%) 5 (19%) 10 (21%) 0.99
Other 59 (80%) 22 (81%) 37 (79%)
Identifying haemophilia/bleeding disorders at birth would help research into a cure by enabling 
more children to be enrolled into clinical trials early on
Agree 18 (24%) 5 (19%) 13 (28%) 0.41
Other 56 (76%) 22 (81%) 34 (72%)
Identifying haemophilia/bleeding disorders at birth would interfere with the early bonding 
process between parent and child
Agree 6 (8%) 2 (7%) 4 (9%) 0.99
Other 68 (92%) 25 (93%) 43 (91%)
Identifying haemophilia/bleeding disorders at birth would make the diagnosis easier for parents 
to accept
Agree 22 (30%) 7 (26%) 15 (32%) 0.79
Other 52 (70%) 20 (74%) 32 (68%)
Identifying haemophilia/bleeding disorders at birth would spare parents the difficulties 
associated with finding a diagnosis for the child later on
Agree 30 (41%) 11 (41%) 19 (40%) 0.99
Other 44 (59%) 16 (59%) 28 (60%)
Even if parents could not know for sure the severety of the haemophilia/bleeding disorder 
affecting their newborn baby, its still better that they know about the bleeding disorder 
straight away
Agree 40 (54%) 13 (48%) 27 (57%) 0.47
Other 34 (46%) 14 (52%) 20 (43%)
Identifying haemophilia/bleeding disorders at birth is important as it would enable parents to 
make informed decisions about future pregnancies
Agree 39 (53%) 16 (59%) 23 (49%) 0.47
Other 35 (47%) 11 (41%) 24 (51%)
It is unethical not to screen newborn babies for conditions that can be treated
Agree 10 (14%) 4 (15%) 6 (13%) 0.99
Other 64 (86%) 23 (85%) 41 (87%)
Responses for each question were stratified as “agree” v “other” (other = disagree and neither disa‐
gree nor agree).
Differences were assessed using chi‐2 analysis (P‐value).
TA B L E  4   Response summaries for 
responders who did not support the 
introduction of NGS. Response 
breakdowns are shown for families and 
AwH
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Given that participants were being asked about a hypothetical 
(rather than already implemented) screening programme, it is also 
possible that participants’ prior knowledge of NGS was limited, a 
fact that may have skewed their attitudes towards it. However, the 
current high profile of genomic medicine within the public and policy 
arena, the fact that all participants had prior experience of a genetic 
disease in their family as well as the relatively recent introduction 
(2006) of an NGS in the UK for another genetic condition, Cystic 
Fibrosis, together meant that participants did not have to make large 
imaginative leaps to envisage the potential transferability of NGS to 
haemophilia, and as such, we do not feel that this lack of background 
knowledge need limit the value of the data.
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